Crowley Erika L, Gooderham Melinda J
Faculty of Medicine, University of British Columbia Okanagan, 3333 University Way, Kelowna, BC V1V 1V7, Canada.
SKiN Centre for Dermatology, 775 Monaghan Rd, Peterborough, ON K9J 5K2, Canada.
Pharmaceutics. 2023 Dec 22;16(1):23. doi: 10.3390/pharmaceutics16010023.
Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase-4 (PDE4) inhibitors are emerging with expanding options. PDE4 inhibitors play a pivotal role in the inflammatory cascade by degrading cyclic adenosine monophosphate (cAMP), contributing to pro-inflammatory mediator production. Apremilast, an oral PDE4 inhibitor, is approved for psoriasis. While effective, its adverse effects can limit its utility. Roflumilast, a topical PDE4 inhibitor, was also recently approved for psoriasis and shows promise in clinical trials. Crisaborole, a PDE4 inhibitor approved for atopic dermatitis, has also been studied in psoriasis. This review summarizes evidence from randomized clinical trials regarding the efficacy and safety of PDE4 inhibitors in psoriasis treatment. By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis management.
银屑病是一种常见的慢性免疫介导性疾病，伴有多种合并症，对生活质量有影响。在银屑病的治疗方法中，磷酸二酯酶4（PDE4）抑制剂的选择越来越多，正在崭露头角。PDE4抑制剂通过降解环磷酸腺苷（cAMP）在炎症级联反应中起关键作用，促进促炎介质的产生。阿普斯特，一种口服PDE4抑制剂，已被批准用于治疗银屑病。虽然有效，但其不良反应可能会限制其应用。罗氟司特，一种外用PDE4抑制剂，最近也被批准用于治疗银屑病，并且在临床试验中显示出前景。克立硼罗，一种已被批准用于特应性皮炎的PDE4抑制剂，也已在银屑病中进行了研究。本综述总结了来自随机临床试验的证据，这些证据涉及PDE4抑制剂在银屑病治疗中的疗效和安全性。通过强调它们的潜在益处和局限性，本综述为旨在优化银屑病管理的临床医生和研究人员提供了有价值的见解。
